Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen’s Phase III Evolocumab Trial Meets Endpoints | Contract Pharma

What are you searching for?

Sign in

Amgen’s Phase III Evolocumab Trial Meets Endpoints

Reduces LDL-C in statin intolerant patients

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen’s Phase III GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2) trial of evolocumab in patients with high cholesterol who can’t tolerate statins, met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C), and the mean percent reduction from baseline in LDL-C.
 
Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove LDL-C from the blood. Safety was generally balanced across treatment groups and the most common adverse events were headache, myalgia, pain in extremity, and muscle spasms.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters